145 related articles for article (PubMed ID: 30095707)
21. Relation between mismatch repair status, chemoresponse, survival and anatomic location in gastroesophageal adenocarcinoma.
Evaristo G; Katz A; Ramírez-GarcíaLuna JL; Issac MSM; Sangwan V; Thai DV; Bertos N; Guiot MC; Camilleri-Broët S; Marcus V; Mueller C; Cools-Lartigue J; Fiset PO; Ferri LE
Can J Surg; 2023; 66(1):E79-E87. PubMed ID: 36792128
[TBL] [Abstract][Full Text] [Related]
22. Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.
Stasenko M; Feit N; Lee SSK; Shepherd C; Soslow RA; Cadoo KA; Alektiar K; Da Silva EM; Martins Sebastião AP; Leitao MM; Gardner G; Selenica P; Abu-Rustum NR; Weigelt B; Mueller JJ
Int J Gynecol Cancer; 2020 Jun; 30(6):717-723. PubMed ID: 32376737
[TBL] [Abstract][Full Text] [Related]
23. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
van der Heide DM; Turaga KK; Chan CHF; Sherman SK
J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
[TBL] [Abstract][Full Text] [Related]
24. Endometrial Cancer Characteristics and Risk of Recurrence.
Borden LE; Locklear TM; Grider DJ; Osborne JL; Saks EJ; Valea FA; Iglesias DA
Am J Clin Pathol; 2022 Jan; 157(1):90-97. PubMed ID: 34463332
[TBL] [Abstract][Full Text] [Related]
25. Definitive radiotherapy for vaginal recurrence of early-stage endometrial cancer: survival outcomes and effect of mismatch repair status.
Alban G; Cheng T; Adleman J; Buzurovic I; Pretz J; Singer L; King M; Lee L
Int J Gynecol Cancer; 2021 Jul; 31(7):1007-1013. PubMed ID: 33858956
[TBL] [Abstract][Full Text] [Related]
26. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients.
Ni K; Zhan Y; Liu Z; Zhao XZ; Wang W; Wang G; Zhang Z; Li G; Zhang X; Zhang C
J Surg Oncol; 2022 Mar; 125(4):692-702. PubMed ID: 34918842
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer.
Fountzilas E; Kotoula V; Pentheroudakis G; Manousou K; Polychronidou G; Vrettou E; Poulios C; Papadopoulou E; Raptou G; Pectasides E; Karayannopoulou G; Chrisafi S; Papakostas P; Makatsoris T; Varthalitis I; Psyrri A; Samantas E; Bobos M; Christodoulou C; Papadimitriou C; Nasioulas G; Pectasides D; Fountzilas G
ESMO Open; 2019; 4(2):e000474. PubMed ID: 31231557
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Survival and Clinicopathological Implications of DNA Mismatch Repair Status in Endometrioid Endometrial Cancers in Hong Kong Chinese Women.
Lee JHS; Li JJX; Chow C; Chan RCK; Kwan JSH; Lau TS; To KF; Yim SF; Yeung SY; Kwong J
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680502
[TBL] [Abstract][Full Text] [Related]
30. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
[TBL] [Abstract][Full Text] [Related]
31. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
Sun CY; Chiang JM; Chen TC; Hung HY; You JF
World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
[TBL] [Abstract][Full Text] [Related]
32. The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis.
Kok PS; Antill YC; Scott CL; Lee CK
ESMO Open; 2022 Dec; 7(6):100635. PubMed ID: 36410086
[TBL] [Abstract][Full Text] [Related]
33. Mismatch repair deficiency in canine neoplasms.
Inanaga S; Igase M; Sakai Y; Tanabe M; Shimonohara N; Itamoto K; Nakaichi M; Mizuno T
Vet Pathol; 2021 Nov; 58(6):1058-1063. PubMed ID: 34538134
[TBL] [Abstract][Full Text] [Related]
34. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
Rowe M; Krishnan R; Mills A; Ring K
Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
[TBL] [Abstract][Full Text] [Related]
35. Mismatch repair proteins expression and tumor-infiltrating T-cells in colorectal cancer.
Shigaki T; Fujiyoshi K; Sudo T; Kawahara A; Nakane H; Yomoda T; Nagasu S; Kinugasa T; Akiba J; Fujita F; Akagi Y
Oncol Lett; 2022 Nov; 24(5):396. PubMed ID: 36276483
[TBL] [Abstract][Full Text] [Related]
36. Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer.
von Loga K; Woolston A; Punta M; Barber LJ; Griffiths B; Semiannikova M; Spain G; Challoner B; Fenwick K; Simon R; Marx A; Sauter G; Lise S; Matthews N; Gerlinger M
Nat Commun; 2020 Jan; 11(1):139. PubMed ID: 31949146
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer.
Oh CR; Kim EJ; Chae H; Park YS; Ryu MH; Kim HD; Kang YK
Gastric Cancer; 2024 Mar; ():. PubMed ID: 38555561
[TBL] [Abstract][Full Text] [Related]
38. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
[TBL] [Abstract][Full Text] [Related]
39. Deciding the operation type according to mismatch repair status among hereditary nonpolyposis colorectal cancer patients: should a tailored approach be applied, or does one size fit all?
Liao CK; Lin YC; Hsu YJ; Chern YJ; You JF; Chiang JM
Hered Cancer Clin Pract; 2021 Jun; 19(1):29. PubMed ID: 34187536
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value and Immunohistochemical Analysis of Mismatch Repair Deficiency in Patients with Stage II and III Colorectal Carcinoma-A Single-Center Study.
Denčić T; Krstić M; Petrović A; Jovičić-Milentijević M; Radenković G; Jović M; Živković N; Šalinger-Martinović S; Branković B; Stojanović S
Medicina (Kaunas); 2020 Dec; 56(12):. PubMed ID: 33302424
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
